Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of IMX101 in H. Pylori-negative and Infected Volunteers
NCT03270800Phase 1Completed
- Sponsor
- ImevaX
- Start
- Jan 2017
- Primary completion
- Dec 2018
- Modality
- Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IMX101 in Helicobacter pylori infection (2 arms), sponsored by ImevaX. Primary endpoint: Safety and tolerability of IMX101 at 215 days. Started Jan 2017; status: completed.
02
Drugs
IMX101
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT03270800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03270800.